Literature DB >> 2105712

Retinal toxicity of recombinant tissue plasminogen activator in the rabbit.

M W Johnson1, K R Olsen, E Hernandez, W D Irvine, R N Johnson.   

Abstract

We studied the dose-dependent retinal toxicity of the available commercial preparation of human recombinant tissue plasminogen activator in the normal rabbit eye. Tissue plasminogen activator was injected into the midvitreous cavity of albino rabbits in doses (per 100 microL) of 25, 50, 75, and 100 micrograms. Control eyes received 100 microL of balanced salt solution or tissue plasminogen activator vehicle. No evidence of a retinal toxic reaction was seen in eyes receiving 25 micrograms of tissue plasminogen activator. One of four eyes injected with 50 micrograms showed loss of photoreceptor cells by light microscopy. Severe retinal damage was seen by ophthalmoscopy, electroretinography, and light microscopy in three of four eyes receiving 75 micrograms of tissue plasminogen activator and in all eyes treated with 100 micrograms of tissue plasminogen activator or equivalent vehicle. These results suggest that the commercial recombinant tissue plasminogen activator formulation has a narrow margin of safety in nonvitrectomized eyes and that a component of the vehicle is the toxic factor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105712     DOI: 10.1001/archopht.1990.01070040111042

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  25 in total

Review 1.  Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.

Authors:  Eric Wakshull; Valerie Quarmby; Hanns-Christian Mahler; Hongwen Rivers; Dhananjay Jere; Meg Ramos; Piotr Szczesny; Karoline Bechtold-Peters; Sharmila Masli; Swati Gupta
Journal:  AAPS J       Date:  2017-08-09       Impact factor: 4.009

2.  Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage.

Authors:  Y Oshima; M Ohji; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

3.  Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.

Authors:  Takeshi Mizutani; Tsutomu Yasukawa; Yuya Ito; Ayae Takase; Yoshio Hirano; Munenori Yoshida; Yuichiro Ogura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-29       Impact factor: 3.117

Review 4.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.

Authors:  Matthias Lüke; Kai Januschowski; Max Warga; Julia Beutel; Martin Leitritz; Faik Gelisken; Salvatore Grisanti; Toni Schneider; Christoph Lüke; Karl Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

6.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

7.  Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation.

Authors:  Chih-Wei Shih; Chung-May Yang; Muh-Shy Chen; Tsung-Jen Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

8.  Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion.

Authors:  T H Mahmoud; Y-W Peng; A D Proia; M Davidson; V A Deramo; S Fekrat
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

9.  Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

Authors:  R P Singh; C Patel; J E Sears
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

10.  Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.

Authors:  Takuhiro Yamamoto; Motohiro Kamei; Paradee Kunavisarut; Mihoko Suzuki; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-25       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.